The enhanced early detection capabilities of the CA125–HE4 multimarker model hold the potential to significantly improve patient outcomes by enabling timely diagnosis, assisting healthcare providers in more accurate clinical decision‐making, and informing policymakers in shaping effective strategies for ovarian cancer screening and management. Here, WFDC2 is linked to ovarian carcinoma.